참고문헌
- Krieg, A. M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709-760 (2002) https://doi.org/10.1146/annurev.immunol.20.100301.064842
- Takeda, K. & Akira, S. Toll-like receptors in innate immunity. Int Immunol 17:1-14 (2005) https://doi.org/10.1093/intimm/dxh186
- Iwasaki, A. & Medzhitov, R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5:987-995 (2004) https://doi.org/10.1038/ni1112
- Akira, S., Takeda, K. & Kaisho, T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2:675-680 (2001) https://doi.org/10.1038/90609
- Chu, R. S., Targoni, O. S., Krieg, A. M., Lehmann, P. V. & Harding, C. V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 186:1623-1631 (1997) https://doi.org/10.1084/jem.186.10.1623
- van Duin, D., Medzhitov, R. & Shaw, A. C. Triggering TLR signaling in vaccination. Trends Immunol 27:49-55 (2006) https://doi.org/10.1016/j.it.2005.11.005
- Klinman, D. M., Yi, A. K., Beaucage, S. L., Conover, J. & Krieg, A. M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 93: 2879-2883 (1996) https://doi.org/10.1073/pnas.93.7.2879
- Klinman, D. M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 4:249-258 (2004) https://doi.org/10.1038/nri1329
- Bhattacharjee, R. N. & Akira, S. Modifying toll-like receptor 9 signaling for therapeutic use. Mini Rev Med Chem 6:287-291 (2006) https://doi.org/10.2174/138955706776073411
- Anders, H. J. et al. Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J 18:534-536 (2004) https://doi.org/10.1096/fj.03-0646fje
- Anders, H. J. A Toll for lupus. Lupus 14:417-422 (2005) https://doi.org/10.1191/0961203305lu2102rr
- Anders, H. J. et al. Bacterial CpG-DNA aggravates immune complex glomerulonephritis: role of TLR9-mediated expression of chemokines and chemokine receptors. J Am Soc Nephrol 14:317-326 (2003) https://doi.org/10.1097/01.ASN.0000042169.23931.73
- Aringer, M. & Smolen, J. S. Cytokine expression in lupus kidneys. Lupus 14:13-18 (2005) https://doi.org/10.1191/0961203305lu2053oa
- Cho, H. C. et al. Cancer immunotherapeutic effects of novel CpG ODN in murine tumor model. Int Immunopharmacol 8:1401-1407 (2008) https://doi.org/10.1016/j.intimp.2008.05.010
- Link, B. K. et al. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother 29:558-568 (2006) https://doi.org/10.1097/01.cji.0000211304.60126.8f
- Friedberg, J. W. et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 105:489-495 (2005) https://doi.org/10.1182/blood-2004-06-2156
- Cooper, C. L. et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 24:693-701 (2004) https://doi.org/10.1007/s10875-004-6244-3
- Gilkeson, G. S. et al. Modulation of renal disease in autoimmune NZB/NZW mice by immunization with bacterial DNA. J Exp Med 183:1389-1397 (1996) https://doi.org/10.1084/jem.183.4.1389
- Gilkeson, G. S. et al. Effects of bacterial DNA on cytokine production by (NZB/NZW)F1 mice. J Immunol 161:3890-3895 (1998)
- Hofmann, M. A. et al. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother 31:520-527 (2008) https://doi.org/10.1097/CJI.0b013e318174a4df
- Lipsky, P. E. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2:764-766 (2001) https://doi.org/10.1038/ni0901-764
- Hayakawa, K., Hardy, R. R., Parks, D. R. & Herzenberg, L. A. The 'Ly-1 B' cell subpopulation in normal immunodefective, and autoimmune mice. J Exp Med 157:202-218 (1983) https://doi.org/10.1084/jem.157.1.202
- Wofsy, D. & Chiang, N. Y. Proliferation of Ly-1 B cells in autoimmune NZB and (NZB×NZW)F1 mice. Eur J Immunol 17:809-814 (1987) https://doi.org/10.1002/eji.1830170612
- Sidman, C. L., Shultz, L. D., Hardy, R. R., Hayakawa, K. & Herzenberg, L. A. Production of immunoglobulin isotypes by Ly-1+ B cells in viable motheaten and normal mice. Science 232:1423-1425 (1986) https://doi.org/10.1126/science.3487115
- Burastero, S. E., Casali, P., Wilder, R. L. & Notkins, A. L. Monoreactive high affinity and polyreactive low affinity rheumatoid factors are produced by CD5+ B cells from patients with rheumatoid arthritis. J Exp Med 168:1979-1992 (1988) https://doi.org/10.1084/jem.168.6.1979
- Viau, M. & Zouali, M. B-lymphocytes, innate immunity, and autoimmunity. Clin Immunol 114:17-26 (2005) https://doi.org/10.1016/j.clim.2004.08.019